Table 2 Pharmaceutical intervention for adverse events

Nausea and vomiting (n = 50)

D2 blocker

24

48.0%

Olanzapine

9

18.0%

Aprepitant

6

12.0%

5-HT3 receptor antagonist

4

8.0%

Proton-pump inhibitor (PPI)

3

6.0%

Mirtazapine

2

4.0%

Others (Camostat/Butylscopolamine/Dexamethasone)

3

6.0%

Peripheral neuropathy (n = 36)

Duloxetine

17

47.2%

Pregabalin/Mirogabalin Cryotherapy

14

38.9%

Dose reduction of oxaliplatin (from 85 mg/m2 to 65 mg/m2)

4

11.1%

1

2.8%

Skin disorder (n = 31)

Steroid cream

12

38.7%

Heparinoids

8

25.8%

H1 receptor blocker

4

12.9%

Antimicrobial agent

3

9.7%

Pemirolast

3

9.7%

Others (Posterisan® forte/Urea cream/Crotamiton)

3

9.7%

Pain (n = 29)

Non-steroidal anti-inflammatory drugs (NSAIDs)

13

44.8%

Opioids

11

37.9%

Acetaminophen

7

24.1%

Shakuyakukanzoto^a

1

3.4%

Oral mucositis (n = 25)

Sodium azulenesulfonate preparation

15

60.0%

Steroid

7

28.0%

Sodium alginate

2

8.0%

Zinc preparation

2

8.0%

Diarrhea (n = 15)

Probiotics

9

60.0%

Loperamide

4

26.7%

Hangeshashinto

3

20.0%

Aluminium silicate

2

13.3%

Others (Butylscopolamine/Alubumin tannate)

2

13.3%

Dysgeusia (n = 12)

Zinc preparation

12

100.0%

Malaise (n = 6)

Tapering of dexamethasone

5

83.3%

Hochuekkito^a

1

16.7%

Edema limbs (n = 4)

Goreisan^a

2

50.0%

Azosemide

1

25.0%

Change from pregabalin to duloxetine

1

25.0%

Constipation (n = 2)

Probiotics

1

50.0%

Sennoside

1

50.0%